Related Experiment Video

Updated: Jun 12, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.3K

Selective killing of castration-resistant prostate cancer cells by formycin A via the ATF4-CHOP axis

Tomoki Takei1,2, Yuki Hamamura1, Hiroshi Hongo3

  • 1Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan.

Cancer Science
|September 27, 2024
PubMed

Insights

Formycin A effectively kills castration-resistant prostate cancer (CRPC) cells by triggering apoptosis. This novel compound also demonstrated significant antitumor effects in vivo, offering a promising new therapeutic avenue for CRPC treatment.

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Molecular Biology

Background:

  • Prostate cancer initially depends on androgens but frequently progresses to castration-resistant prostate cancer (CRPC).
  • Existing therapies for CRPC show limited effectiveness, necessitating the development of new treatment strategies.

Purpose of the Study:

  • To identify novel therapeutic agents for castration-resistant prostate cancer (CRPC).
  • To investigate the efficacy and mechanism of action of formycin A in CRPC models.

Main Methods:

  • Conducted a drug screen using an established aggressive CRPC cell model.
  • Evaluated formycin A's effect on CRPC cell viability and apoptosis.
  • Assessed formycin A's in vivo antitumor activity in CRPC xenograft models.

Main Results:

  • Formycin A selectively induced cell death in CRPC model cells, sparing parental prostate cancer cells.
  • Formycin A upregulated death receptor 5 via endoplasmic reticulum stress, activating the extrinsic apoptosis pathway in CRPC cells.
  • Formycin A exhibited significant in vivo antitumor efficacy against CRPC xenografts in castrated nude mice.

Conclusions:

  • Formycin A demonstrates potent anti-CRPC activity through apoptosis induction.
  • Formycin A represents a potential novel therapeutic agent for treating castration-resistant prostate cancer.
Keywords:
CRPCER stressantitumor activitydeath receptor 5formycin A

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy09:59

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

17.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K